This spring, Phillips Eye & Surgery Center in Flemington, N.J., will hold an exhibit of artwork from Hunterdon Regional High School and Hunterdon Watercolor Society, according to an NJ.com report.
Ophthalmology
R-Tech Ueno, Japanese pharmaceutical company, has filed for and received FDA IND approval to begin Phase I and II clinical trials of its severe dry eye treatment, RU -101.
Pharm-Olam International, contract research organization for InSite Vision, has completed a Phase 3 clinical trial of BromSite, an anti-inflammatory designed to reduce swelling and pain after cataract surgery.
A three-year study led by Andrew Lotery, MD, ophthalmologist and professor at Southampton General Hospital in the U.K., has found that 65 percent of liver transplant patients developed age-related macular degeneration within five years of receiving the transplant, according to…
The American Academy of Ophthalmology "Want Scary Eyes?" campaign was launched in 2011 to promote consumer awareness of the dangers of using non-prescription decorative contact lens and has featured over 1,500 news stories and several audio news releases.
Advertisement
Lausanne, Switzerland-based Sensimed AG has announced that it will be presenting its Sensimed Triggerfish at the Association for Research in Vision and Ophthalmology 2013 meeting.
OptiMedica, Sunnyvale, Calif.-based ophthalmic device company, has announced it will be showing 31 clinical presentations of its Catalys Precision Laser System at the American Society of Cataract and Refractive Surgery 2013 conference, according to a report by Laser Focus World.
Paul Kang, MD, and Thomas Clinch, MD, of the private practice Eye Doctors of Washington in Washington, D.C., have announced the acquisition of the WaveLight EX500 Excimer laser.
Helga Pizio, MD, and her Las Vegas practice New Eyes has announced a merger with Todd Hartman, MD, Doug Devries, MD, and Paul Hiss, MD, of Eye Care Associates of Nevada.
Alcon, ophthalmology division of Swiss pharmaceutical company Novartis, has received FDA approval for Simbrinza, the company's fixed-dose combination glaucoma therapy, according to a report by thepharmaletter.